Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:31:04.469Z.
Calculation as of: 2026-10-06T13:31:04.469Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4980e4284b6230c79d3dcd5f09fe919c7c05eb80d65ab6e095ba480293e97312
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Canton Strategic Holdings Inc
Market Cap
$180.47M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$178.29M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$178.17M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.12M
EV/EBITDA Ratio
145.81x
TTM Avg
155.63x
3Y Avg
70.41x
5Y Avg
70.41x
Market Cap
$174.59M
EV/EBITDA Ratio
N/A
TTM Avg
8.39x
3Y Avg
66.32x
5Y Avg
66.32x
Market Cap
$195.29M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $180.47M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $178.29M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $178.17M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $184.12M | 145.81x | 155.63x | 70.41x | 70.41x |
| Cue Biopharma, Inc. (CUE)vs › | $175.94M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $174.59M | N/A | 8.39x | 66.32x | 66.32x |
| AN2 Therapeutics, Inc. (ANTX)vs › | $194.13M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $195.29M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $160.82M | N/A | 29.09x | 58.55x | 59.27x |
| ALX Oncology Holdings Inc. (ALXO)vs › | $160.13M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
